

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

### Listing of Claims:

- 1-46. (Cancelled).
47. (Currently Amended): A soluble immunoglobulin-polypeptide chimera comprising an immunoglobulin having a CDR<sub>3</sub> region, wherein a diabetogenic epitope comprising a polypeptide having amino acid sequence of SEQ ID No: 4 is inserted within the CDR<sub>3</sub> region.
48. (Cancelled).
49. (Cancelled).
50. (Cancelled).
51. (Cancelled).
52. (Cancelled).
53. (Cancelled).
54. (Previously Presented): The chimera of claim 47 wherein the chimera is capable of being endocytosed by Fc receptor cells and processed by said cells to present the at least one protein fragment or peptide to endogenous MHC Class II molecules, thereby reducing or preventing activation of T cells specific for the diabetogenic epitope.
55. (Previously Presented): The chimera of claim 47 wherein the immunoglobulin comprises IgG.
56. (Previously Presented): The chimera of claim 55 wherein said IgG is human IgG or humanized IgG.
57. (Cancelled).
58. (Cancelled).
59. (Currently Amended): The chimera of claim 47, wherein the wherein at least one diabetogenic epitope replaces a D segment region within said CDR<sub>3</sub> region.
60. (Cancelled).
61. (Previously presented): A pharmaceutical composition comprising a chimera according to claim 47 and a pharmaceutically acceptable carrier.

62. (Cancelled).
63. (Cancelled.
64. (Cancelled).
65. (Cancelled).